- $1.84bn
- $1.82bn
- $105.97m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 21.88 | ||
| PEG Ratio (f) | 0.44 | ||
| EPS Growth (f) | 98.66% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 22.91 | ||
| Price to Tang. Book | 27.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 49.6 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.48% | ||
| Return on Equity | -72.31% | ||
| Operating Margin | -418.99% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 26.68 | 412.48 | 76.01 | 76.3 | 105.97 | 297.47 | 294.25 | 22.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +17.85 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zymeworks Inc. is a global biotechnology company building a diversified portfolio of healthcare assets. The Company's asset and royalty aggregation strategy combines a portfolio of commercial and near-commercial assets, including YUPELRI (revefenacin), with a differentiated internal research and development engine. The Company's portfolio also includes Ziihera (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by it and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using the Company's proprietary antibody engineering technologies. The Company is advancing a diverse pipeline of novel biotherapeutics, leveraging its proprietary Azymetric platform and expertise in antibody-drug conjugates, multispecific antibodies and other next-generation antibody technologies. Its product candidates include ZW191, ZW251, ZW220, ZW209 and ZW1528.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 30th, 2022
- Public Since
- June 24th, 2019
- No. of Shareholders
- 72
- No. of Employees
- 231
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 71,509,241
- Address
- 108 Patriot Drive, Suite A, MIDDLETOWN, 19709
- Web
- https://www.zymeworks.com
- Phone
- +1 3022748744
- Auditors
- KPMG LLP
Latest News for ZYME
Upcoming Events for ZYME
Q3 2026 Zymeworks Inc Earnings Release
Zymeworks Inc. Annual Shareholders Meeting
Zymeworks Inc Annual Shareholders Meeting
Q4 2026 Zymeworks Inc Earnings Release
Similar to ZYME
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 06:22 UTC, shares in Zymeworks are trading at $25.75. This share price information is delayed by 15 minutes.
Shares in Zymeworks last closed at $25.75 and the price had moved by +38.29% over the past 365 days. In terms of relative price strength the Zymeworks share price has outperformed the S&P500 Index by +18.38% over the past year.
The overall consensus recommendation for Zymeworks is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreZymeworks does not currently pay a dividend.
Zymeworks does not currently pay a dividend.
Zymeworks does not currently pay a dividend.
To buy shares in Zymeworks you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $25.75, shares in Zymeworks had a market capitalisation of $1.84bn.
Here are the trading details for Zymeworks:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ZYME
Based on an overall assessment of its quality, value and momentum Zymeworks is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Zymeworks is $41.67. That is 61.83% above the last closing price of $25.75.
Analysts covering Zymeworks currently have a consensus Earnings Per Share (EPS) forecast of $1.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zymeworks. Over the past six months, its share price has underperformed the S&P500 Index by -14.97%.
As of the last closing price of $25.75, shares in Zymeworks were trading +2.78% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Zymeworks PE ratio based on its reported earnings over the past 12 months is 21.88. The shares last closed at $25.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Zymeworks' management team is headed by:
- Kenneth Galbraith - CHM
- Neil Klompas - CFO
- Neil Josephson - OTH
- Lota Zoth - LED